Evidence map›Paper›PMID 23955427›Full record

ArticleJournal of surgical oncology2013

Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer.

Brian A Boone, Jennifer Steve, Alyssa M Krasinskas, Amer H Zureikat, Barry C Lembersky, Michael K Gibson, Ronald G Stoller, Herbert J Zeh, Nathan Bahary

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of surgical oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 9 pooled it
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 9 syntheses or guidelines pooled it, 190 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Brian A BooneDepartment of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Jennifer Steve
Alyssa M Krasinskas
Amer H Zureikat
Barry C Lembersky
Michael K Gibson
Ronald G Stoller
Herbert J Zeh
Nathan Bahary
University of Pittsburgh · US

Funding

Postdoctoral Research Training in Biotherapy of CancerT32CA113263 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Udai S Kammula · 2006 to 2026
$3.6M
NCI NIH HHS T32 CA113263NCI NIH HHS T32CA113263
6 · The paper itself

Abstract

backgroundTrials examining FOLFIRINOX in metastatic pancreatic cancer demonstrate higher response rates compared to gemcitabine-based regimens. There is currently limited experience with neoadjuvant FOLFIRINOX in pancreatic cancer.

methodsRetrospective review of outcomes of patients with borderline resectable or locally unresectable pancreatic cancer who were recommended to undergo neoadjuvant treatment with FOLFIRINOX.

resultsFOLFIRINOX was recommended for 25 patients with pancreatic cancer, 13 (52%) unresectable and 12 (48%) borderline resectable. Four patients (16%) refused treatment or were lost to follow-up. Twenty-one patients (84%) were treated with a median of 4.7 cycles. Six patients (29%) required dose reductions secondary to toxicity. Two patients (9%) were unable to tolerate treatment and three patients (14%) had disease progression on treatment. Seven patients (33%) underwent surgical resection following treatment with FOLFIRINOX alone, 2 (10%) of which were initially unresectable. Two patients underwent resection following FOLFIRINOX + stereotactic body radiation therapy (SBRT). The R0 resection rate for patients treated with FOLFIRINOX ± SBRT was 33% (55% borderline resectable, 10% unresectable). A total of five patients (24%) demonstrated a significant pathologic response.

conclusionsFOLFIRINOX is a biologically active regimen in borderline resectable and locally unresectable pancreatic cancer with encouraging R0 resection and pathologic response rates.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsCamptothecinCombined Modality TherapyFemaleFluorouracilHumansIrinotecanMaleMiddle AgedOrganoplatinum CompoundsOxaliplatinPancreatic NeoplasmsRadiosurgeryRetrospective StudiesCamptothecinFluorouracilIrinotecanOrganoplatinum CompoundsOxaliplatinborderline resectablelocally unresectableneoadjuvant treatmentpancreatic cancer: FOLFIRINOX

Identifiers

PMID23955427
PMCPMC3816713
OpenAlexW1530374458

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.